• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抗体依赖增强作用:疫苗开发中不可避免的问题。

Antibody dependent enhancement: Unavoidable problems in vaccine development.

机构信息

College of Veterinary Medicine, Northwest A&F University, Yangling, Shaanxi, China.

College of Veterinary Medicine, Northwest A&F University, Yangling, Shaanxi, China.

出版信息

Adv Immunol. 2021;151:99-133. doi: 10.1016/bs.ai.2021.08.003. Epub 2021 Sep 14.

DOI:10.1016/bs.ai.2021.08.003
PMID:34656289
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8438590/
Abstract

In some cases, antibodies can enhance virus entry and replication in cells. This phenomenon is called antibody-dependent infection enhancement (ADE). ADE not only promotes the virus to be recognized by the target cell and enters the target cell, but also affects the signal transmission in the target cell. Early formalin-inactivated virus vaccines such as aluminum adjuvants (RSV and measles) have been shown to induce ADE. Although there is no direct evidence that there is ADE in COVID-19, this potential risk is a huge challenge for prevention and vaccine development. This article focuses on the virus-induced ADE phenomenon and its molecular mechanism. It also summarizes various attempts in vaccine research and development to eliminate the ADE phenomenon, and proposes to avoid ADE in vaccine development from the perspective of antigens and adjuvants.

摘要

在某些情况下,抗体可以增强病毒在细胞中的进入和复制。这种现象称为抗体依赖性感染增强(ADE)。ADE 不仅促进了病毒被靶细胞识别并进入靶细胞,还影响了靶细胞中的信号转导。已证明早期的福尔马林灭活病毒疫苗(如铝佐剂(RSV 和麻疹))会引起 ADE。尽管没有直接证据表明 COVID-19 中存在 ADE,但这种潜在风险对预防和疫苗开发来说是一个巨大的挑战。本文重点介绍了病毒诱导的 ADE 现象及其分子机制。它还总结了疫苗研发中消除 ADE 现象的各种尝试,并从抗原和佐剂的角度提出了在疫苗开发中避免 ADE 的建议。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e495/8438590/693191f75c19/f03-01-9780128245996_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e495/8438590/693191f75c19/f03-01-9780128245996_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e495/8438590/693191f75c19/f03-01-9780128245996_lrg.jpg

相似文献

1
Antibody dependent enhancement: Unavoidable problems in vaccine development.抗体依赖增强作用:疫苗开发中不可避免的问题。
Adv Immunol. 2021;151:99-133. doi: 10.1016/bs.ai.2021.08.003. Epub 2021 Sep 14.
2
Two Different Antibody-Dependent Enhancement (ADE) Risks for SARS-CoV-2 Antibodies.两种不同的 SARS-CoV-2 抗体依赖增强(ADE)风险。
Front Immunol. 2021 Feb 24;12:640093. doi: 10.3389/fimmu.2021.640093. eCollection 2021.
3
Role of antibody-dependent enhancement (ADE) in the virulence of SARS-CoV-2 and its mitigation strategies for the development of vaccines and immunotherapies to counter COVID-19.抗体依赖性增强(ADE)在 SARS-CoV-2 毒力中的作用及其在开发疫苗和免疫疗法以对抗 COVID-19 方面的缓解策略。
Hum Vaccin Immunother. 2020 Dec 1;16(12):3055-3060. doi: 10.1080/21645515.2020.1796425. Epub 2020 Aug 26.
4
Multiple Routes of Antibody-Dependent Enhancement of SARS-CoV-2 Infection.抗体依赖性增强作用促进 SARS-CoV-2 感染的多种途径。
Microbiol Spectr. 2022 Apr 27;10(2):e0155321. doi: 10.1128/spectrum.01553-21. Epub 2022 Mar 23.
5
[The Challenges of Vaccine Development Against Betacoronaviruses: Antibody Dependent Enhancement and Sendai Virus as a Possible Vaccine Vector].[针对β冠状病毒研发疫苗的挑战:抗体依赖性增强作用以及仙台病毒作为一种可能的疫苗载体]
Mol Biol (Mosk). 2020 Nov-Dec;54(6):922-938. doi: 10.31857/S0026898420060154.
6
Antibody-Dependent Enhancement with a Focus on SARS-CoV-2 and Anti-Glycan Antibodies.抗体依赖性增强作用,重点关注 SARS-CoV-2 和抗聚糖抗体。
Viruses. 2023 Jul 20;15(7):1584. doi: 10.3390/v15071584.
7
Out of the frying pan and into the fire? Due diligence warranted for ADE in COVID-19.是否会“福无双至,祸不单行”?对 COVID-19 中的治疗药物附加条件应持谨慎态度。
Microbes Infect. 2020 Oct;22(9):405-406. doi: 10.1016/j.micinf.2020.06.006. Epub 2020 Jun 24.
8
Waning antibodies from inactivated SARS-CoV-2 vaccination offer protection against infection without antibody-enhanced immunopathology in rhesus macaque pneumonia models.灭活 SARS-CoV-2 疫苗产生的抗体衰减提供了针对感染的保护,而不会在恒河猴肺炎模型中引起抗体增强的免疫病理学。
Emerg Microbes Infect. 2021 Dec;10(1):2194-2198. doi: 10.1080/22221751.2021.2002670.
9
A review: Antibody-dependent enhancement in COVID-19: The not so friendly side of antibodies.综述:COVID-19 中的抗体依赖性增强作用:抗体不那么友好的一面。
Int J Immunopathol Pharmacol. 2021 Jan-Dec;35:20587384211050199. doi: 10.1177/20587384211050199.
10
Antibody Dependent Enhancement of SARS-CoV-2 Infection in the Era of Rapid Vaccine Development.抗体依赖性增强作用促进 SARS-CoV-2 感染:在疫苗快速开发时代。
Med Arch. 2022 Oct;76(5):383-386. doi: 10.5455/medarh.2022.76.383-386.

引用本文的文献

1
Antibody-dependent enhancement of SARS-CoV-2, the impact of variants and vaccination.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的抗体依赖性增强作用、变异株及疫苗接种的影响
Hum Vaccin Immunother. 2025 Dec;21(1):2505356. doi: 10.1080/21645515.2025.2505356. Epub 2025 May 24.
2
Beyond the Pandemic Era: Recent Advances and Efficacy of SARS-CoV-2 Vaccines Against Emerging Variants of Concern.后疫情时代:SARS-CoV-2疫苗针对新出现的关注变异株的最新进展与效果
Vaccines (Basel). 2025 Apr 17;13(4):424. doi: 10.3390/vaccines13040424.
3
Antibody-dependent enhancement of coronaviruses.

本文引用的文献

1
In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies.SARS-CoV-2 感染增强和中和抗体的体外和体内功能。
Cell. 2021 Aug 5;184(16):4203-4219.e32. doi: 10.1016/j.cell.2021.06.021. Epub 2021 Jun 18.
2
An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies.新冠病毒刺突蛋白上一个被抗体靶向的增强感染性位点。
Cell. 2021 Jun 24;184(13):3452-3466.e18. doi: 10.1016/j.cell.2021.05.032. Epub 2021 May 24.
3
Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD.
冠状病毒的抗体依赖性增强作用。
Int J Biol Sci. 2025 Feb 3;21(4):1686-1704. doi: 10.7150/ijbs.96112. eCollection 2025.
4
A Comprehensive Review of mRNA-based Vaccines for COVID-19, A New Era in Pharmaceuticals: Unspecified and Unknown Aspects, Effects and Challenges.新型冠状病毒肺炎mRNA疫苗综合综述:制药新时代的未明确及未知方面、影响与挑战
Curr Top Med Chem. 2025;25(12):1467-1491. doi: 10.2174/0115680266325847241121034100.
5
Prophylactic and therapeutic vaccine development: advancements and challenges.预防性和治疗性疫苗的研发:进展与挑战。
Mol Biomed. 2024 Nov 11;5(1):57. doi: 10.1186/s43556-024-00222-x.
6
Analysis of Beyfortus (Nirsevimab) Immunization Campaign: Effectiveness, Biases, and ADE Risks in RSV Prevention.Beyfortus(尼塞韦单抗)免疫接种活动分析:呼吸道合胞病毒预防中的有效性、偏倚和不良事件风险
Curr Issues Mol Biol. 2024 Sep 18;46(9):10369-10395. doi: 10.3390/cimb46090617.
7
Co-expression of VP2, NS1 and NS2-Nt proteins by an MVA viral vector induces complete protection against bluetongue virus.MVA 病毒载体共表达 VP2、NS1 和 NS2-Nt 蛋白可诱导对蓝舌病病毒的完全保护。
Front Immunol. 2024 Jul 12;15:1440407. doi: 10.3389/fimmu.2024.1440407. eCollection 2024.
8
Efficacy of genotype-matched vaccine against re-emerging genotype V Japanese encephalitis virus.基因型匹配疫苗对重现的基因型 V 日本脑炎病毒的效力。
Emerg Microbes Infect. 2024 Dec;13(1):2343910. doi: 10.1080/22221751.2024.2343910. Epub 2024 Apr 29.
9
Recognition of Mosquito Saliva Protein LTRIN by the Human Receptor LTβR for Controlling the Immune Response.人类受体LTβR对蚊唾液蛋白LTRIN的识别以控制免疫反应。
Biology (Basel). 2024 Jan 12;13(1):42. doi: 10.3390/biology13010042.
10
Genomic similarity and antibody-dependent enhancement of immune serum potentially affect the protective efficacy of commercial MLV vaccines against NADC30-like PRRSV.基因组相似性和免疫血清的抗体依赖性增强可能会影响针对 NADC30 样 PRRSV 的商业 MLV 疫苗的保护效力。
Virol Sin. 2023 Oct;38(5):813-826. doi: 10.1016/j.virs.2023.08.010. Epub 2023 Sep 1.
恢复期供体的 SARS-CoV-2 抗体的增强作用与中和作用与 RBD 上的不同表位相关。
Cell Rep. 2021 Feb 2;34(5):108699. doi: 10.1016/j.celrep.2021.108699. Epub 2021 Jan 12.
4
Enhancement of Zika virus infection by antibodies from West Nile virus seropositive individuals with no history of clinical infection.西尼罗河病毒血清阳性且无临床感染史个体的抗体增强寨卡病毒感染。
BMC Immunol. 2021 Jan 9;22(1):5. doi: 10.1186/s12865-020-00389-2.
5
Genomic characteristics and pathogenicity of a new recombinant strain of porcine reproductive and respiratory syndrome virus.猪繁殖与呼吸综合征病毒新重组毒株的基因组特征与致病性
Arch Virol. 2021 Feb;166(2):389-402. doi: 10.1007/s00705-020-04917-8. Epub 2021 Jan 1.
6
Role of the complement system in antibody-dependent enhancement of flavivirus infections.补体系统在抗体依赖性增强黄病毒感染中的作用。
Int J Infect Dis. 2021 Feb;103:404-411. doi: 10.1016/j.ijid.2020.12.039. Epub 2020 Dec 19.
7
Antibody-dependent enhancement (ADE) of dengue virus: Identification of the key amino acid that is vital in DENV vaccine research.抗体依赖性增强(ADE)作用:鉴定关键氨基酸在登革热疫苗研究中的重要性。
J Gene Med. 2021 Feb;23(2):e3297. doi: 10.1002/jgm.3297. Epub 2021 Jan 17.
8
A complement component C1q-mediated mechanism of antibody-dependent enhancement of Ebola virus infection.补体成分 C1q 介导的抗体依赖性增强埃博拉病毒感染的机制。
PLoS Negl Trop Dis. 2020 Sep 4;14(9):e0008602. doi: 10.1371/journal.pntd.0008602. eCollection 2020 Sep.
9
A perspective on potential antibody-dependent enhancement of SARS-CoV-2.对 SARS-CoV-2 潜在抗体依赖性增强作用的看法。
Nature. 2020 Aug;584(7821):353-363. doi: 10.1038/s41586-020-2538-8. Epub 2020 Jul 13.
10
Challenges in Dengue Vaccines Development: Pre-existing Infections and Cross-Reactivity.登革热疫苗研发面临的挑战:既往感染和交叉反应。
Front Immunol. 2020 Jun 16;11:1055. doi: 10.3389/fimmu.2020.01055. eCollection 2020.